Pertussis vaccination in pregnancy, dTaP/IPV (Boostrix-IPV® or Repevax®): PGD template

PGD template to support the national pertussis vaccination for pregnant women immunisation programme.


Diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) for pregnant women: patient group direction (PGD) template

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This patient group direction (PGD) template supports the administration of low dose diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) by currently registered nurses or midwives.

This applies to women from 16 weeks of pregnancy in accordance with the pertussis vaccination for pregnant women national immunisation programme for active immunisation of the pregnant woman and to provide passive immunity in the neonate against pertussis. It is valid from 1 April 2017 to 31 March 2019.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 7 January 2016
Last updated 6 April 2017 + show all updates
  1. Updated vaccine eligibility changed from 20 weeks to 16 weeks of pregnancy.
  2. Updated pertussis pregnancy PGD: vaccine eligibility changed from 28 to 20 weeks of pregnancy.
  3. First published.